




**Figure S1.** Silvestrol inhibits eIF4A-dependent translation. A549 cells were treated with the indicated amount of silvestrol. Cells lysates of the indicated time points were analyzed by Western blot with specific antibodies against PIM1 and  $\beta$ -actin.



**Figure S2.** Toxic effect of 100 nM silvestrol in primary human hepatocytes. PHHs were treated with the indicated concentrations of silvestrol. 24 h, 48 h, and 72 h post treatment PrestoBlue assay (**A**) and brightfield imaging (**B**) were performed.





**Figure S3.** No inhibiting effect of silvestrol on the IRES-dependent translation of HCV. Huh7.5 cells were transfected with the full length HCV genome Jc1 and 72 h post transfection treated with the indicated concentrations of silvestrol. **(A)** Cells lysates of the indicated time points were analyzed by Western blot with specific antibodies against NS3, NS5A and  $\beta$ -actin. **(B)** Quantification of NS3 of densitometry scans exemplary shown in A). **(C)** Quantification of NS5A of densitometry scans exemplary shown in A).



**Figure S4.** Silvestrol exerts its antiviral effect also with higher MOI. (A) Quantification of intracellular ZIKV RNA of A549 cells infected with ZIKV FP (MOI=1) and treated with the indicated concentrations of silvestrol. ZIKV RNA was quantified by RT-qPCR and normalized to the amount of RPL27 transcripts; (B) Quantification of intracellular ZIKV RNA of A549 cells infected with ZIKV U (MOI=1) and treated with the indicated concentrations of silvestrol. ZIKV RNA was quantified by RT-qPCR and normalized to the amount of RPL27 transcripts; (C) RT-qPCR quantification of extracellular ZIKV RNA of A549 cells infected with ZIKV FP (MOI=1) and treated with the indicated concentrations of silvestrol; (D) RT-qPCR quantification of extracellular ZIKV RNA of A549 cells infected with ZIKV U (MOI=1) and treated with the indicated concentrations of silvestrol; (E) Western Blot analysis of A549 cells infected with ZIKV FP (MOI=1) and treated with the

indicated concentrations of silvestrol; (F) Quantification of NS1 of densitometry scans exemplary shown in E); (G) Western Blot analysis of A549 cells infected with ZIKV U (MOI=1) and treated with the indicated concentrations of silvestrol; (H) Quantification of NS1 of densitometry scans exemplary shown in G).



**Figure S5.** Silvestrol decreases the amount of the antiviral protein MVP. A549 cells were treated with the indicated concentrations of silvestrol. (A) 24 h after treatment cells were fixed with icecold ethanol. Nuclei were stained with DAPI (blue) and MVP was stained with an antibody (red); (B) cell lysates were analyzed by Western Blot analysis with antibodies against MVP and actin.